Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 72

2.

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.

Liu J, Nie XY, Zhang Y, Lu Y, Shi LW, Wang WM.

Chin Med J (Engl). 2015 Aug 20;128(16):2183-8. doi: 10.4103/0366-6999.162515.

3.

Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.

Sardella G, Calcagno S, Mancone M, Lucisano L, Pennacchi M, Stio RE, Placentino F, Di Roma A, Cavallo E, Palmirotta R, Guadagni F, Fedele F.

Int J Cardiol. 2015 Sep 1;194:60-2. doi: 10.1016/j.ijcard.2015.05.085. Epub 2015 May 15. No abstract available.

PMID:
26011265
4.

Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.

Hokimoto S, Akasaka T, Tabata N, Arima Y, Tsujita K, Sakamoto K, Kaikita K, Morita K, Kumagae N, Yamamoto E, Oniki K, Nakagawa K, Ogawa H.

Thromb Res. 2015 Jun;135(6):1081-6. doi: 10.1016/j.thromres.2015.03.033. Epub 2015 Apr 11.

PMID:
25891840
5.

CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419.

Samardzic J, Bozina N, Skoric B, Ganoci L, Petricevic M, Krpan M, Pasalic M, Milicic D.

Int J Cardiol. 2015;186:282-5. doi: 10.1016/j.ijcard.2015.03.171. Epub 2015 Mar 17. No abstract available.

PMID:
25828136
6.

The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.

Tang N, Yin S, Sun Z, Xu X, Qin J.

Scand J Clin Lab Invest. 2015 May;75(3):223-9. doi: 10.3109/00365513.2014.993696. Epub 2015 Jan 16.

PMID:
25594796
7.

Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.

Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T.

Thromb Res. 2015 Mar;135(3):449-58. doi: 10.1016/j.thromres.2014.12.007. Epub 2014 Dec 9. Review.

PMID:
25511576
8.

Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.

Qiu LN, Sun Y, Wang L, Han RF, Xia XS, Liu J, Li X.

Eur J Pharmacol. 2015 Jan 15;747:29-35. doi: 10.1016/j.ejphar.2014.11.037. Epub 2014 Dec 6.

PMID:
25489921
9.

Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.

Palmerini T, Calabrò P, Piscione F, De Servi S, Cattaneo M, Maffeo D, Toso A, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Barozzi C, Tomasi L, Della Riva D, Mariani A, Taglieri N, Reggiani LB, Bianchi R, De Rosa R, Mariani M, Podda G, Généreux P, Stone GW, Angiolillo DJ.

JACC Cardiovasc Interv. 2014 Oct;7(10):1117-27. doi: 10.1016/j.jcin.2014.04.020. Epub 2014 Sep 17.

10.

Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.

Arima Y, Hokimoto S, Akasaka T, Mizobe K, Kaikita K, Oniki K, Nakagawa K, Ogawa H.

J Cardiol. 2015 Jun;65(6):494-500. doi: 10.1016/j.jjcc.2014.07.016. Epub 2014 Aug 22.

PMID:
25156215
11.
12.

Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.

Diodati JG, Saucedo JF, Cardillo TE, Jakubowski JA, Henneges C, Effron MB, Lipkin FR, Walker JR, Duvvuru S, Sundseth SS, Fisher HN, Angiolillo DJ.

Thromb Haemost. 2014 Aug;112(2):311-22. doi: 10.1160/TH13-09-0747. Epub 2014 Apr 10.

PMID:
24718367
13.

Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.

Kim H, Kim Y, Koh YS, Lee HK, Chae H, Jekarl DW, Lee JM, Shin WS, Kim TH.

Platelets. 2015;26(2):148-53. doi: 10.3109/09537104.2014.889291. Epub 2014 Mar 11.

PMID:
24617511
14.

CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.

Liu T, Yin T, Li Y, Song LQ, Yu J, Si R, Zhang YM, He Y, Guo WY, Wang HC.

Coron Artery Dis. 2014 Aug;25(5):412-20. doi: 10.1097/MCA.0000000000000092.

PMID:
24608794
15.

Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel.

Choi JL, Kim BR, Kim JE, Woo KS, Kim KH, Kim JM, Kim MH, Han JY.

Int J Lab Hematol. 2014 Oct;36(5):e80-3. doi: 10.1111/ijlh.12194. Epub 2014 Mar 3. No abstract available.

PMID:
24589079
16.

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.

Hokimoto S, Mizobe M, Akasaka T, Arima Y, Kaikita K, Nakagawa K, Ogawa H.

Thromb Res. 2014 Apr;133(4):599-605. doi: 10.1016/j.thromres.2014.01.003. Epub 2014 Jan 9.

PMID:
24440142
17.

The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.

Tatarunas V, Jankauskiene L, Kupstyte N, Skipskis V, Gustiene O, Grybauskas P, Lesauskaite V.

Blood Coagul Fibrinolysis. 2014 Jun;25(4):369-74. doi: 10.1097/MBC.0000000000000053.

PMID:
24418943
18.

Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.

Valgimigli M.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S8-S15. doi: 10.2459/JCM.0b013e328364bd25. Review.

PMID:
24378839
19.

Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.

Cattaneo M.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S16-21. doi: 10.2459/JCM.0b013e328364bd3a. Review.

PMID:
24378837
20.

Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes.

Jeong YH, Bliden KP, Shuldiner AR, Tantry US, Gurbel PA.

Thromb Haemost. 2014 Apr 1;111(4):713-24. doi: 10.1160/TH13-08-0643. Epub 2013 Dec 12.

PMID:
24336898
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk